Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-20, Stock:LLY, The news for the past five days is as follows:
2018-07-13: NEWS1: Here are Q2&apos;s 10 biggest VC-backed exits from the Bay Area.NEWS2: Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom.NEWS3: Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom.NEWS4: Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom.NEWS5: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS6: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS7: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.
2018-07-16: NEWS1: Analyst Recommendations for Valeant Pharmaceuticals in July.NEWS2: J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay.NEWS3: J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay.NEWS4: J&J&apos;s (JNJ) Invokana Label Expansion Filing Hit by FDA Delay.NEWS5: The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon.
2018-07-17: nan
2018-07-18: NEWS1: Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon.NEWS2: Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon.NEWS3: Estimates and Recommendations for Eli Lilly on July 18.NEWS4: Pfizer, Eli Lilly non-opioid pain drug nears finish line.NEWS5: Eli Lilly’s Q2 2018 Estimates: Expect Revenue Growth.NEWS6: Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon.NEWS7: What to Expect from Eli Lilly and Company’s Q2 2018 Earnings.NEWS8: Pfizer-Lilly pain drug meets late-stage trial goals.NEWS9: Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain.NEWS10: Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab.NEWS11: Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab.
2018-07-19: NEWS1: Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE).NEWS2: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS3: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS4: Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study.NEWS5: Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study.NEWS6: LLY vs. NVO: Which Stock Is the Better Value Option?.NEWS7: LLY vs. NVO: Which Stock Is the Better Value Option?.NEWS8: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS9: Pfizer & Lilly&apos;s Pain Candidate Succeeds in Phase III Study.NEWS10: The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon.NEWS11: The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon.NEWS12: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS13: Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint.NEWS14: The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon.NEWS15: Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease.NEWS16: Lilly: Tradjenta's CARMELINA Cardiovascular Outcome Trial Meets Primary Endpoint.NEWS17: Lilly: Tradjenta's CARMELINA Cardiovascular Outcome Trial Meets Primary Endpoint.

Answer: Decrease